A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease

Trial Profile

A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Mongersen (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 28 Sep 2017 Planned End Date changed from 28 Oct 2019 to 29 Oct 2019.
    • 28 Sep 2017 Planned primary completion date changed from 26 Jan 2018 to 23 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top